Thermo Fisher Scientific Launches New Quality Assurance Software
Thermo Fisher Scientific has released LabLink 360 Quality Assurance software, a new digital tool designed to streamline quality control (QC) workflows and accelerate decision-making in clinical laboratories. This software aims to enhance visibility into QC performance, automate routine review steps, and provide real-time peer group benchmarking. LabLink 360 integrates with the MAS Quality Controls portfolio and is intended to help laboratories manage operations more proactively, especially given the frequency of out-of-control QC events.
Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches
Thermo Fisher Scientific announced that its Applied Biosystems RapidINTEL Plus Cartridge has received FBI approval for use with forensic crime scene samples on the RapidHIT ID System. This milestone allows qualifying Rapid DNA-generated profiles to be searched against the national CODIS database, expediting investigations by providing DNA intelligence in hours instead of days or weeks. The approval expands the utility of Rapid DNA technology, enabling faster identification of suspects or exclusion of individuals while adhering to FBI quality standards and laboratory oversight.
ICON Stock Outlook 2026 as Margin Woes Meet a Stronger Backlog Base
ICON plc (ICLR) is facing an uneven investment profile as it enters the second half of 2026. While customer demand and bookings show improvement, the company struggles with profitability, declining margins, and internal control issues. Despite a stronger backlog, a "Strong Sell" Zacks Rank and mixed style scores suggest caution for investors until earnings stabilize and margins recover.
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market
Shares of Thermo Fisher Scientific Inc. fell by 1.12% on Monday, closing at $517.60, despite a positive overall day for the stock market. This decline snapped a two-day winning streak for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average both saw gains on the same day.
How Azenta’s Dual Russell 2000 Defensive Index Addition Will Impact Azenta (AZTA) Investors
Azenta, Inc. (NasdaqGS: AZTA) was recently added to both the Russell 2000 Value-Defensive Index and the Russell 2000 Defensive Index, which could increase its visibility among institutional investors. While this inclusion may boost liquidity, it does not fundamentally alter the near-term earnings pressure or the risk of strain on margins due to higher spending and soft spots in core services. Additionally, despite a fair value estimate aligning with its current price and projected revenue growth, concerns about margin pressure and execution remain among analysts.
Thermo Fisher expands Brazil manufacturing with new research plant
Thermo Fisher Scientific is constructing a new plant in Barueri, Brazil, to produce biological research media for export, leveraging growing demand for clinical research in the region. This expansion is part of a broader strategy, including significant global acquisitions, to support the pharmaceutical industry, particularly biotechnology, and diversify into sectors requiring ultrapure water. The company also integrates AI into its scientific workflows through partnerships with OpenAI and Nvidia to accelerate clinical trials and enhance research capabilities.
Top 10 medtech deals in the first half of 2026
Medtech companies engaged in significant merger and acquisition activity during the first half of 2026, building on previous high deal volumes. This period saw $36.5 billion in acquisitions, with companies like Boston Scientific, Medtronic, and Stryker making strategic moves to enter fast-growing markets or divest from slower areas. The top deal was Boston Scientific's $14.5 billion acquisition of Penumbra, alongside other notable transactions by Danaher, Roche, and Agilent.
Evercore ISI Adjusts Price Target on Thermo Fisher Scientific to $570 From $575
Evercore ISI has adjusted its price target for Thermo Fisher Scientific (NYSE: TMO) to $570, a slight decrease from its previous target of $575. The article highlights other recent news concerning Thermo Fisher, including collaborations and analyst recommendations. Thermo Fisher Scientific specializes in laboratory and scientific equipment, diagnostics, and related services, with significant operations in North America and Europe.
Evercore ISI Adjusts Thermo Fisher Scientific Price Target to $204 From $205
Evercore ISI has adjusted its price target for Thermo Fisher Scientific (NYSE: TMO) to $204, down from the previous $205. This news was published on July 6, 2026, at 08:58 am EDT by MT Newswires. The article provides this key update along with a brief company profile for Thermo Fisher Scientific.
Are Analyst Upgrades Signaling a Turning Point in Charles River’s (CRL) Biopharma Pipeline Narrative?
Analyst upgrades for Charles River Laboratories International (CRL) from Morgan Stanley and CLSA indicate a more positive outlook due to stronger biopharma funding and a supportive regulatory environment in China. This shift contrasts with recent concerns regarding softer organic revenue and weaker returns, suggesting that momentum and regulatory tailwinds could reshape expectations for the company's future work pipeline. While the upgrades provide a brighter long-term view, Charles River's near-term guidance still projects a revenue decline, emphasizing that the positive trends must translate into improved bookings to materialize fully.
GRAL - GRAIL Inc Volatility & Greeks
This article provides a detailed financial overview of GRAIL Inc. (GRAL), including key metrics such as market capitalization, income, sales, various performance ratios, and stock performance indicators. It also lists insider and institutional ownership, analyst recommendations, and volatility measures. The data reflects the company's financial health, operational efficiency, and market sentiment, with the last close at $68.95.
How Investors May Respond To Thermo Fisher Scientific (TMO) Deepening Its Role In Late‑Stage mRNA Manufacturing
Thermo Fisher Scientific has deepened its involvement in late-stage mRNA manufacturing through a collaboration with Arcturus Therapeutics for the ARCT-032 cystic fibrosis therapy. This agreement strengthens Thermo Fisher's position as an end-to-end development partner in complex biologics. The company's investment narrative continues to focus on its role as a diversified provider to the pharmaceutical industry, with upcoming Q2 2026 earnings and potential impacts from China exposure and tariff pressures also being key considerations for investors.
Precision Trading with Thermo Fisher Scientific Inc (TMO) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Thermo Fisher Scientific Inc (TMO) using AI-driven precision trading strategies. It highlights a 47.4:1 risk-reward setup, targeting a 13.7% gain with only 0.3% risk, and outlines specific entry and exit zones for long, breakout, and short strategies based on strong near and mid-term sentiment. The analysis includes multi-timeframe signal analysis with defined support and resistance levels.
Waters Corporation focuses on analytical science amid steady demand
Waters Corporation (US9418481035) is a major provider of analytical instruments and laboratory solutions, with a strong presence in pharmaceuticals, life sciences, food, and environmental testing. The company's business model integrates instrument hardware, software, services, and consumables, ensuring recurring revenue and long-term customer relationships. Its strategic focus on core technologies like chromatography and mass spectrometry, coupled with ongoing innovation and a global footprint, underpins its resilience and growth in highly regulated end markets.
3 Stocks For Investors Hunting Value After The Tech Bubble Reset
As the tech bubble resets, investors are increasingly looking for value stocks with strong cash flows, dividends, and tangible assets rather than growth stories based on hype. This article highlights three companies—SLB, Thermo Fisher Scientific, and SEGRO—that offer a blend of traditional valuation appeal and potential for resilience in the current market environment. Each company is presented with its operational overview, market capitalization, and specific reasons why it might be an attractive investment for those seeking value after the tech market correction, along with potential risks.
Terrestrial Energy names Tyler Gronbach VP of investor relations By Investing.com
Terrestrial Energy Inc. has appointed Tyler Gronbach as its Vice President of Investor Relations and Public Relations. This strategic move aims to strengthen the company's communications as it progresses towards commercializing its Integral Molten Salt Reactor technology, especially following its Nasdaq listing. Gronbach brings extensive experience from previous roles at Wolfspeed, Inc. and Thermo Fisher Scientific, where he managed significant capital raises and communications strategies.
CRL - Charles River Laboratories International Inc Latest SEC Filings
This article provides a detailed financial overview and recent SEC filing information for Charles River Laboratories International Inc (CRL). It covers key financial metrics, stock performance data, analyst ratings, and details on insider and institutional ownership, offering a comprehensive snapshot of the company's current market position.
OPK - Opko Health Inc Options
This article provides a comprehensive overview of Opko Health Inc. (OPK) stock, including its latest closing price, key financial metrics, performance indicators, and ownership details. It details statistics such as market capitalization, income, sales, P/E ratio, EPS, insider and institutional ownership, and various performance percentages over different periods.
Thermo Fisher Scientific (TMO) Wins Arcturus mRNA Role, Is The Upside Already Priced In?
Thermo Fisher Scientific (TMO) has gained attention after being selected as Arcturus Therapeutics' partner for an investigational mRNA therapy. Despite a recent share price rebound and a "14.4% Undervalued" narrative with a fair value of $611.56, Simply Wall St questions if the upside is already priced in, highlighting potential risks such as weak academic funding and China-related pressures. The article encourages investors to review data and consider both risks and rewards for their investment thesis.
WAT - Waters Corp Latest SEC Filings
This article provides the latest SEC filings and a comprehensive financial overview for Waters Corp (WAT). It details key financial metrics, stock performance data, insider transaction information, and analyst recommendations, offering a snapshot of the company's current market position and financial health.
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
Arcturus Therapeutics (ARCT) stock jumped 5.7% after the company announced a strategic collaboration with Thermo Fisher Scientific for the phase III development and commercialization of its cystic fibrosis mRNA therapy, ARCT-032. While the stock saw a significant gain, its near-term outlook is cautious, holding a Zacks Rank #3 (Hold), due to unchanged consensus EPS estimates for the upcoming quarter despite strong revenue and earnings expectations. The article suggests investors monitor future earnings estimate revisions to determine if the recent strength will continue.
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to advance its investigational mRNA therapy, ARCT-032, for Cystic Fibrosis. This partnership will leverage Thermo Fisher's Accelerator™ Drug Development solutions for integrated manufacturing, clinical research, and commercial readiness services, supporting ARCT-032's Phase 3 development and potential commercialization. The agreement includes provisions for exclusive commercial manufacturing rights for Thermo Fisher if ARCT-032 receives regulatory approval.
Charles River Laboratories International Non-Executive Director James Foster Sells 27% Of Holding
James Foster, a Non-Executive Director at Charles River Laboratories International, recently sold US$17 million worth of company stock, reducing his total holding by 27%. This sale, though substantial, is notable as the largest insider sale in the past year, even at a share price below current levels. Despite this insider selling, the company still boasts 1.1% insider ownership, valued at US$125 million, which generally aligns management interests with shareholders, though the selling activity suggests caution.
ILMN - Illumina Inc Volatility & Greeks
This article provides a detailed snapshot of Illumina Inc. (ILMN) financial and stock performance data as of July 2, 2026. It includes key metrics such as market capitalization, income, sales, various P/E ratios, EPS growth rates, insider and institutional ownership, profitability margins, and volatility indicators. The data highlights recent price changes, trading volumes, and performance over different periods.
Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market
Shares of Thermo Fisher Scientific Inc. (TMO) rose 1.97% to $523.44 on Thursday, marking its second consecutive day of gains. The stock outperformed the broader market, which experienced a mixed trading session with the S&P 500 Index remaining mostly unchanged and the Dow Jones Industrial Average rising.
A - Agilent Technologies Inc Latest SEC Filings
This article provides comprehensive financial data for Agilent Technologies Inc (A), including its latest stock performance, key financial metrics, valuation ratios, and institutional ownership. As of July 2nd, the stock closed at $130.69, reflecting a 2.02% decrease, with a market capitalization of $36.91 billion. The filing details various performance indicators, analyst recommendations, and upcoming earnings information.
Arcturus taps Thermo Fisher to make its cystic fibrosis therapy
Arcturus Therapeutics has partnered with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, their investigational mRNA therapy for Cystic Fibrosis. Thermo Fisher will provide integrated manufacturing, clinical research, and commercial readiness services, leveraging its Accelerator™ Drug Development solutions. This collaboration aims to accelerate the delivery of ARCT-032 to patients, with Thermo Fisher receiving exclusive commercial manufacturing rights upon regulatory approval.
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Arcturus Therapeutics has announced a strategic collaboration with Thermo Fisher Scientific to advance ARCT-032, their investigational mRNA therapy for Cystic Fibrosis. This partnership will leverage Thermo Fisher's Accelerator™ Drug Development solutions for Phase 3 development and potential commercialization, including manufacturing and clinical research services. The agreement aims to accelerate the delivery of this innovative therapy to patients, with Thermo Fisher providing exclusive commercial manufacturing rights upon regulatory approval.
Thermo Fisher to back Arcturus (NASDAQ: ARCT) ARCT-032 Phase 3 and manufacturing
Arcturus Therapeutics has announced a strategic collaboration with Thermo Fisher Scientific to advance its investigational mRNA therapy, ARCT-032, for cystic fibrosis through Phase 3 development and potential commercialization. Thermo Fisher will contribute up to $40 million in clinical manufacturing services and its PPD business will provide up to $40 million in contract research organization services. Upon regulatory approval, Thermo Fisher will gain exclusive commercial manufacturing rights for ARCT-032.
Arcturus stock rises on pact with Thermo Fisher (ARCT:NASDAQ)
Arcturus Therapeutics stock rose after announcing a partnership with Thermo Fisher Scientific. The collaboration aims to advance ARCT-032, Arcturus's experimental messenger RNA therapy for cystic fibrosis. This agreement has positively impacted investor sentiment for Arcturus.
Charles River Laboratories International (CRL) On Lilly TuneLab Deal And The Valuation Debate
Charles River Laboratories International (CRL) has partnered with Lilly TuneLab, an AI drug discovery platform, to provide nonclinical testing services, leading to a significant rally in its stock price. The article discusses varied valuations for CRL, with Simply Wall St's popular narrative suggesting a 27% undervaluation at $313.61, partly due to a strategic acquisition of a non-human primate supplier. Conversely, a DCF model from the same source indicates the stock might be overvalued at its current price of $229.09, suggesting a fair value of $76.49.
IDXX - Idexx Laboratories Inc Volatility & Greeks
This article provides a detailed financial overview of Idexx Laboratories Inc. (IDXX), including its current stock performance, key financial metrics, volatility indicators, and analyst recommendations. It covers various data points from market capitalization to insider transactions and performance across different timeframes, offering a comprehensive snapshot of the company's financial health and stock behavior.
DGX - Quest Diagnostics Inc Options
This article provides a comprehensive financial overview of Quest Diagnostics Inc. (DGX), including its market performance, valuation metrics, dividend information, and growth rates. Key financial data points such as P/E ratio, market capitalization, sales, and various performance indicators are detailed.
Press Release: Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
Thermo Fisher Scientific will host an earnings conference call on Thursday, July 23, 2026. The call will discuss the company's financial results for the second quarter of 2026. Investors and interested parties can access the call to learn about the company's performance.
OneTest growth vision: 20/20 Biolabs (AIDX) targets Medicare MCED market
20/20 Biolabs (AIDX) outlined its OneTest multi-cancer early detection strategy, which includes a focus on future Medicare reimbursement and a protein biomarker-based test. The company is aligning its strategy with the new Multi-Cancer Early Detection Screening Coverage Act, aiming for Medicare coverage of MCED tests starting in 2028, contingent on FDA authorization and CMS clinical appropriateness. The presentation also detailed an M&A strategy targeting health-and-wellness businesses and included hypothetical revenue projections and a royalty pool for "data investors."
Waters Corporation highlights analytical science role amid steady industry demand
Waters Corporation continues to be a crucial supplier of analytical instruments, supporting laboratories and pharmaceutical companies with precision measurement technology. The company's business model relies on instrument sales, consumables, software, and services, catering to long-term demand driven by pharmaceutical R&D, environmental monitoring, and food safety testing. Its stock offers investors exposure to the life sciences tools segment, characterized by recurring revenue and ties to regulated industries, positioning it as an infrastructure provider for scientific workflows.
Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market
Shares of Thermo Fisher Scientific Inc. (TMO) rose 2.39% to $513.33 on Wednesday, outperforming the broader market. This rise snapped a two-day losing streak for the company's stock, despite a generally rough trading session where both the S&P 500 and Dow Jones Industrial Average saw declines.
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
Thermo Fisher Scientific (NYSE: TMO) announced it will release its second-quarter 2026 financial results before market open on Thursday, July 23, 2026. The company will hold a conference call that same day at 8:30 a.m. ET to discuss its financial performance and future expectations. The call will be webcast live on the "Investors" section of their website, with replay available until October 21, 2026.
Thermo Fisher’s Q2 results land July 23, with a call at 8:30 a.m.
Thermo Fisher Scientific Inc. (TMO) will release its second-quarter 2026 financial results before market open on Thursday, July 23, 2026. The company will hold a conference call at 8:30 a.m. ET on the same day to discuss its financial performance and future expectations. The call will be webcast live on the "Investors" section of their website.
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
Thermo Fisher Scientific Inc. announced it will release its second-quarter 2026 financial results before the market opens on Thursday, July 23, 2026. The company will hold a conference call at 8:30 a.m. ET on the same day to discuss its financial performance and future expectations. The call will be webcast live and accessible via a dial-in number, with a replay available until October 21, 2026.
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
Thermo Fisher Scientific Inc. announced it will release its second-quarter 2026 financial results on Thursday, July 23, 2026, before market open. The company will host a conference call on the same day at 8:30 a.m. ET to discuss its financial performance and future expectations. A live webcast of the call will be available on the "Investors" section of their website, with a replay accessible until October 21, 2026.
Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
Eurobio Scientific has completed its acquisition of CareDx’s Lab Products division, integrating it with its GenDx affiliate. This strategic move aims to create a global leader in in-vitro molecular diagnostics for transplantation, enhancing capabilities in genomic typing and expanding product portfolios for HLA typing and transplant monitoring. The acquisition will bolster Eurobio Scientific's presence in key markets and accelerate innovation in transplantation diagnostics.
MYGN - Myriad Genetics Inc Latest SEC Filings
This article provides the latest SEC filings and detailed financial data for Myriad Genetics Inc. (MYGN), including key metrics like market capitalization, income, sales, P/E ratios, and stock performance data. It also lists insider and institutional ownership, profitability margins, and various technical indicators, offering a comprehensive snapshot of the company's financial health and stock activity.
Form 4 Thermo Fisher Scientific For: 30 June By Investing.com
This article from Investing.com reports the filing of Form 4 for Thermo Fisher Scientific (TMO) for June 30. It's a brief financial disclosure, typical for insider trading reports, mentioning the company's stock symbol and a slight dip in its stock performance. The article primarily functions as a placeholder for this financial update.
Thermo Fisher (NYSE: TMO) director awarded new phantom stock units as deferred pay
Thermo Fisher Scientific director Scott M. Sperling was granted 82.84 Phantom Stock Units as part of his deferred compensation, valued at $513.03 per unit. These units are convertible 1-for-1 into Common Stock upon the cessation of his board service or a change of control. Following this award, Sperling now holds a total of 17,674.64 Phantom Stock Units.
Medtronic PLC Stock (MDT) Closed Down by 3.30% on Jun 30: Key Drivers Unveiled
Medtronic PLC (MDT) stock closed down 3.30% on June 30 due to a broader capital rotation out of defensive healthcare stocks into growth sectors, disappointing fiscal 2027 guidance, and increased trading volatility from FTSE Russell index reconstitution and ex-dividend adjustments. The company faces ongoing challenges including tariff headwinds, regulatory recalls, and intense competition in surgical robotics, despite some positive technical indicators. Analysts maintain a mixed view, with an average price target of $97.91, but significant bearish options activity suggests caution.
AustinPx Expands KinetiSol™ Technology Commercial Access through Thermo Fisher Scientific Collaboration
AustinPx has announced a collaboration with Thermo Fisher Scientific's Patheon pharma services to expand the commercial access of its KinetiSol™ Technology. The agreement involves installing KinetiSol equipment at Thermo Fisher's Bend, Oregon, and Cincinnati, Ohio, sites, allowing for development, scale-up, and commercial manufacturing of KinetiSol-enabled drugs. This partnership provides AustinPx clients with an additional pathway for late-stage and commercial manufacturing, strengthening the KinetiSol ecosystem and validating the technology's commercial relevance.
Thermo Fisher Scientific Expands HLA-DQ Testing Coverage for Transplant Antibody Assessment
Thermo Fisher Scientific has launched the LABScreen Single Antigen HLA Class II ExPlex – Group 2 panel, expanding its HLA-DQ testing capabilities. This new panel adds 27 HLA-DQ antigens and heterodimer combinations, enabling more comprehensive antibody assessment for transplant matching and post-transplant monitoring. The expansion allows laboratories to better assess immunological risk in complex transplant cases without workflow modifications or new instrumentation, though it is not yet available in the U.S. or Canada.
Danaher Corp adjusts guidance after Masimo deal. Analysts highlight cautious upside for the stock
Danaher Corp has updated its 2026 earnings guidance to $8.35-$8.55 per share following its acquisition of Masimo Corporation, despite a 22% year-to-date share price decline. Analysts have initiated coverage with a "Neutral" rating and a $200 price target, citing fair valuation and ongoing sector headwinds. The company reported strong Q1 2026 operating metrics and order growth, suggesting a disconnect between fundamental progress and market sentiment.
AustinPx Expands KinetiSol™ Technology Commercial Access through Thermo Fisher Scientific Collaboration
AustinPx has announced a collaboration with Thermo Fisher Scientific's Patheon pharma services to expand commercial access to its KinetiSol™ Technology. This agreement will see KinetiSol equipment installed at Thermo Fisher's oral solid drug manufacturing sites in Bend, Oregon, and Cincinnati, Ohio, enabling comprehensive support from development to commercial manufacturing. The partnership makes Thermo Fisher the exclusive third-party CDMO provider for KinetiSol Formulator technology, offering an integrated pathway for KinetiSol-enabled products.
